繁體版 / 簡體版
 
NEWS ROOM
/ NEWS ROOM
2018-09-07
Fountain Biopharma Inc. Granted Taiwan Patent for Cancer stem cell culture platform

Fountain Biopharma Inc. announces a platform of in vitro co-culture system for cancer-associated fibroblasts and cancer cells was received patent from Taiwan Intellectual property office (TIPO).

Title of the patent is “CANCER-ASSOCIATED FIBROBLASTS IN MAINTAINING STEMNESS OF CANCER STEM CELLS”, patent No. I634209.

This platform is an in vitro co-culture system for cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for screening drugs capable of inhibiting cancer stem cells. Also disclosed a paracrine signaling  for maintaining  cancer stemness could use to predict the drug response rate and prognosis in the cancer patients.

In the future, we could use this platform to discover the novel cancer stem cell markers, therapeutic targets and mechanism.


陕西快乐十分中奖技巧 在线人工时时彩计划 彩票停售通知2020元旦 暴雪彩票官方网站-点击登陆 即时比分直播 上海麻将 北京快3路公交车路线 甘肃11选5爱彩乐 竞彩足球专家推荐预测 举报胡乐麻将平台 亿客隆 捷克酷喜乐彩铅怎么样 一分赛车1至6怎么选号 单机麻将四人免费下载大众麻将 幸运快三可以破解吗怎么破解 新疆彩票时时彩 河南11选5历史开奖号码是多少钱